Trellis Bioscience discovers and develops novel human antibody therapeutics as treatment for infectious disease and oncology indications. The company leverages its proprietary platform technology, CellSpot™, to find rare human antibodies with superior selectivity, affinity and other characteristics. The company has built a pipeline of monoclonal antibodies focused on infectious disease, with the most advanced being an IND candidate for treatment of Respiratory Syncytial Virus, licensed to Medimmune.
January 21, 2013
Trellis VP of R&D, Bill Usinger, was selected to present a talk describing the results of CellSpot™ deep screening of the immune repertoire of the OMT human transgenic rat at PEGS, held in Boston April 29-30, 2013